The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.
Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.
- Johnson & Johnson
- Pfizer, Inc.
- Eli Lilly & Co.
- Bristol-Myers Squibb Company
- Glaxo SmithKline, Plc
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Antipsychotic Drugs Market Variables, Trends & Scope
4 Antipsychotic Drugs Market: Drug Class Estimates & Trend Analysis
5 Antipsychotic Drugs Market: Application Estimates & Trend Analysis
6 Antipsychotic Drugs Market: Regional Estimates & Trend Analysis, by Drug Class and Application
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/svv5xz/antipsychotic